Impact Therapeutics, Inc.
Records under this name other than the patents Impact Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Back to Impact Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,825,246 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,133,900 | Use of Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases Formerly held In force · High confidence | In force | High confidence | |
| US 8,138,199 | Use of Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases Formerly held In force · High confidence | In force | High confidence | |
| US 7,528,143 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,090,568 | Quinazolinediones and their use Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,391,094 | Compositions and Methods for Treating Myelofibrosis Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,358,955 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,179,392 | Solid pharmaceutical formulation of PARP inhibitors and use thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,562,889 | Process for the preparation of 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,703,759 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones Formerly held In force · USPTO record | In force | USPTO record |